

CONTENTS

<i>Contributors</i>	<i>xi</i>
<i>Preface</i>	<i>xvii</i>
<i>Volume in Series</i>	<i>xxi</i>
1. General Principles of Retrovirus Vector Design	1
Tammy Chang and Jiing-Kuan Yee	
1. Introduction	1
2. Construction of Retroviral Vectors Carrying the Gene of Interest	4
3. Transient Production of Retroviral Vectors	6
4. Titering of Retroviral Vectors	9
5. RCR Detection	11
Acknowledgments	12
References	12
2. Strategies for Retrovirus-Based Correction of Severe, Combined Immunodeficiency (SCID)	15
Alain Fischer, Salima Hacein-Bey-Abina, and Marina Cavazzana-Calvo	
1. Early Attempts	17
2. Technological Progress	18
3. Gene Therapy of SCID-X1	18
4. Gene Therapy for ADA Deficiency	22
5. Conclusions	23
References	24
3. Retrovirus and Lentivirus Vector Design and Methods of Cell Conditioning	29
Samantha Cooray, Steven J. Howe, and Adrian J. Thrasher	
1. Introduction	30
2. Retrovirus and Lentivirus Vector Design	34
3. Retroviral and Lentiviral Vector Production	40
4. Transduction Procedures	45
References	53

4. Analysis of the Clonal Repertoire of Gene-Corrected Cells in Gene Therapy	59
Anna Paruzynski, Hanno Glimm, Manfred Schmidt, and Christof von Kalle	
1. Introduction	60
2. Analysis of the Clonal Repertoire by Performing nrLAM-PCR	61
3. Preparation of nrLAM-PCR Samples for High-Throughput Sequencing	73
4. Estimation of the Clonal Contribution by RT-PCR	78
References	85
5. Developing Novel Lentiviral Vectors into Clinical Products	89
Anna Leath and Kenneth Cornetta	
1. Introduction	90
2. Developing a Development Plan	90
3. Development of a GMP Production Method	93
4. Certification Testing of Novel Vector Products	100
Acknowledgments	104
References	105
6. Lentivirus Vectors in β-Thalassemia	109
Emmanuel Payen, Charlotte Colomb, Olivier Negre, Yves Beuzard, Kathleen Hehir, and Philippe Leboulch	
1. Introduction to the β -Thalassemias	110
2. Principles of Lentiviral Gene Therapy for β -Thalassemias	111
3. Clinical Vector Design (LentiGlobin TM)	112
4. cGMP Lentiviral Vector Production	113
5. cGMP Transduction of CD34 ⁺ Cells	113
6. GTP and GMO Release Testing	114
7. Clinical Protocol	114
8. Outcome for the First Thalassemia Patient Treated by Gene Therapy (51 Months Post-transplantation)	121
References	122
7. Gene Therapy for Chronic Granulomatous Disease	125
Elizabeth M. Kang and Harry L. Malech	
1. Introduction	126
2. Vector Design	130
3. Vector Production	132
4. Preclinical Testing of Vector Titer and Transgene Function (<i>In Vitro</i> Culture, Mouse Knockout (KO) CGD Models, and Mouse Models of Human CD34 ⁺ HSC Xenograft)	134
5. Clinical Scale Production	137

6. Target Cell	139
7. Clinical Transduction	140
8. Patient Care and Monitoring	142
9. Future Endeavors	145
10. Conclusion	149
References	150
8. Alternative Splicing Caused by Lentiviral Integration in the Human Genome	155
Arianna Moiani and Fulvio Mavilio	
1. Introduction	156
2. Analysis of Aberrantly Spliced Transcripts Generated by the Integration of SIN Lentiviral Vectors in Human Genes	158
Acknowledgments	168
References	168
9. Genotoxicity Assay for Gene Therapy Vectors in Tumor Prone <i>Cdkn2a</i>^{-/-} Mice	171
Eugenio Montini and Daniela Cesana	
1. Introduction	172
2. <i>In Vivo</i> Genotoxicity Assays Based on Transduction and Transplantation of Tumor-Prone HSPCs	173
References	183
10. Lentiviral Hematopoietic Cell Gene Therapy for X-Linked Adrenoleukodystrophy	187
Nathalie Cartier, Salima Hacein-Bey-Abina, Cynthia C. Bartholomae, Pierre Bougnères, Manfred Schmidt, Christof Von Kalle, Alain Fischer, Marina Cavazzana-Calvo, and Patrick Aubourg	
1. X-linked Adrenoleukodystrophy	188
2. Hematopoietic Stem Cell Transplantation in X-ALD	189
3. Mechanism of Allogeneic HCT Efficacy in X-ALD	189
4. Lentiviral HSC Gene Therapy in X-ALD	189
5. Design and Production of the Lentiviral Vector	190
6. Transduction of CD34 ⁺ Cells from ALD Patients	191
7. Release Testing	192
8. Clinical Protocol	192
9. Patient Biological Follow-up	193
10. Neurological Outcome of the Two Treated Patients	195
References	197

11. Retroviral Replicating Vectors in Cancer	199
Christopher R. Logg, Joan M. Robbins, Douglas J. Jolly, Harry E. Gruber, and Noriyuki Kasahara	
1. Introduction	200
2. Virus Production by Transient Transfection	202
3. Vector Copy Number Assay for Titer Determination and Biodistribution Studies	205
4. Development of Novel RRV Using Molecular Evolution	211
5. MTS Assay of RRV-Mediated Cell Killing <i>In Vitro</i>	215
6. <i>In Vivo</i> Glioma Model for Testing RRV-Mediated Gene Therapy	218
Acknowledgments	225
References	225
12. Adeno-Associated Virus Vectorology, Manufacturing, and Clinical Applications	229
Joshua C. Grieger and R. Jude Samulski	
1. Adeno-Associated Virus Biology	230
2. AAV Vectorology	231
3. rAAV Manufacturing Methods	238
4. Recent Clinical Trials Utilizing rAAV Vectors	240
5. Conclusion	245
Acknowledgments	246
References	246
13. Gene Delivery to the Retina: From Mouse to Man	255
Jean Bennett, Daniel C. Chung, and Albert Maguire	
1. Introduction	256
2. Nucleic Acid Delivery to the Outer Retina in the Mouse	257
3. Nucleic Acid Delivery to the Outer Retina in the Dog	261
4. Nucleic Acid Delivery to the Outer Retina in the Non-Human Primate	265
5. Nucleic Acid Delivery to the Outer Retina in the Human	267
Acknowledgments	270
References	270
14. Generation of Hairpin-Based RNAi Vectors for Biological and Therapeutic Application	275
Ryan L. Boudreau and Beverly L. Davidson	
1. Introduction	276
2. Selecting Candidate siRNA Sequences	278
3. Cloning shRNA Expression Cassettes	280
4. Cloning Artificial miRNA Expression Vectors	285

5. Screening RNAi Vectors for Silencing Efficacy <i>In Vitro</i>	291
6. Integration into Viral Vectors	293
7. Summary	294
References	294
15. Recombinant Adeno-Associated Viral Vector Reference Standards	297
Philippe Moullier and Richard O. Snyder	
1. Introduction	298
2. Utility of Reference Standards	298
3. Volunteer Working Groups	300
4. The AAV2 Reference Standard Material	301
5. The AAV8 Reference Standard Material	302
6. Methods Used to Characterize the AAV RSMs	303
7. Conclusions	308
Acknowledgments	308
References	309
16. NIH Oversight of Human Gene Transfer Research Involving Retroviral, Lentiviral, and Adeno-associated Virus Vectors and the Role of the NIH Recombinant DNA Advisory Committee	313
Marina O'Reilly, Allan Shipp, Eugene Rosenthal, Robert Jambou, Tom Shih, Maureen Montgomery, Linda Gargiulo, Amy Patterson, and Jacqueline Corrigan-Curay	
1. Introduction	314
2. A Brief History of the <i>NIH Guidelines</i> and Recombinant DNA Research Oversight	315
3. Role of the NIH and RAC in Review and Oversight of Human Gene Transfer Involving Retroviral, Lentiviral, and Adeno-associated Virus Vectors	322
4. Conclusion	334
References	334
17. Regulatory Structures for Gene Therapy Medicinal Products in the European Union	337
Bettina Klug, Patrick Celis, Melanie Carr, and Jens Reinhardt	
1. Regulatory Requirements for ATMPs—Marketing Authorization	339
2. Annex I—Part IV to Directive 2001/83/EC	340
3. Definition of Gene Therapy Medicinal Products	341
4. Committee for Advanced Therapies	342

5. CAT–Stakeholder Interaction	345
6. Incentives—Small- and Medium-Sized Enterprise Office (SME Office) at EMA	346
7. National Support Structures	348
8. The role of Patients' Organizations in the Process of Development of Gene Therapy Medicinal Products	349
9. Rare Diseases and Orphan Medicinal Products	350
10. The Role of European Research Networks	351
Acknowledgments	352
References	352
<i>Author Index</i>	355
<i>Subject Index</i>	377